These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
408 related articles for article (PubMed ID: 32271252)
1. The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen. Taramasso L; Berruti M; Briano F; Di Biagio A AIDS; 2020 May; 34(6):877-881. PubMed ID: 32271252 [TBL] [Abstract][Full Text] [Related]
2. Lipid profile changings after switching from rilpivirine/tenofovir disoproxil fumarate/emtricitabine to rilpivirine/tenofovir alafenamide/emtricitabine: Different effects in patients with or without baseline hypercholesterolemia. Taramasso L; Di Biagio A; Riccardi N; Briano F; Di Filippo E; Comi L; Mora S; Giacomini M; Gori A; Maggiolo F PLoS One; 2019; 14(10):e0223181. PubMed ID: 31603906 [TBL] [Abstract][Full Text] [Related]
3. Evaluating emtricitabine + rilpivirine + tenofovir alafenamide in combination for the treatment of HIV-infection. Mu Y; Pham M; Podany AT; Cory TJ Expert Opin Pharmacother; 2020 Mar; 21(4):389-397. PubMed ID: 31957507 [No Abstract] [Full Text] [Related]
4. Switching to a rilpivirine/emtricitabine/tenofovir single-tablet regimen in RNA-suppressed patients infected with human immunodeficiency virus 1: Effectiveness, safety and costs at 96 weeks. Arrabal-Durán P; Rodríguez-González CG; Chamorro-de-Vega E; Gijón-Vidaurreta P; Herranz-Alonso A; Sanjurjo-Sáez M Int J Clin Pract; 2017 Aug; 71(8):. PubMed ID: 28722790 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety 48 weeks after switching from efavirenz to rilpivirine using emtricitabine/tenofovir disoproxil fumarate-based single-tablet regimens. Mills AM; Cohen C; Dejesus E; Brinson C; Williams S; Yale KL; Ramanathan S; Wang MH; White K; Chuck SK; Cheng AK HIV Clin Trials; 2013; 14(5):216-23. PubMed ID: 24144898 [TBL] [Abstract][Full Text] [Related]
6. Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial. Brunetta J; Moreno Guillén S; Antinori A; Yeni P; Wade B; Johnson M; Shalit P; Ebrahimi R; Johnson B; Walker I; De-Oertel S Patient; 2015 Jun; 8(3):257-67. PubMed ID: 25808940 [TBL] [Abstract][Full Text] [Related]
7. Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study. Sculier D; Gayet-Ageron A; Battegay M; Cavassini M; Fehr J; Hirzel C; Schmid P; Bernasconi E; Calmy A; BMC Infect Dis; 2017 Jul; 17(1):476. PubMed ID: 28683720 [TBL] [Abstract][Full Text] [Related]
8. Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis. Behrens G; Rijnders B; Nelson M; Orkin C; Cohen C; Mills A; Elion RA; Vanveggel S; Stevens M; Rimsky L; Thorpe D; Bosse M; White K; Zhong L; DeMorin J; Chuck SK AIDS Patient Care STDS; 2014 Apr; 28(4):168-75. PubMed ID: 24660840 [TBL] [Abstract][Full Text] [Related]
9. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials. Hagins D; Orkin C; Daar ES; Mills A; Brinson C; DeJesus E; Post FA; Morales-Ramirez J; Thompson M; Osiyemi O; Rashbaum B; Stellbrink HJ; Martorell C; Liu H; Liu YP; Porter D; Collins SE; SenGupta D; Das M HIV Med; 2018 Nov; 19(10):724-733. PubMed ID: 30101539 [TBL] [Abstract][Full Text] [Related]
10. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. Orkin C; DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Vandercam B; de Wet J; Rockstroh J; Lazzarin A; Rijnders B; Podzamczer D; Thalme A; Stoeckle M; Porter D; Liu HC; Cheng A; Quirk E; SenGupta D; Cao H Lancet HIV; 2017 May; 4(5):e195-e204. PubMed ID: 28259777 [TBL] [Abstract][Full Text] [Related]
11. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study. DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Martorell CT; de Wet J; Stellbrink HJ; Molina JM; Post FA; Valero IP; Porter D; Liu Y; Cheng A; Quirk E; SenGupta D; Cao H Lancet HIV; 2017 May; 4(5):e205-e213. PubMed ID: 28259776 [TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes in the single-tablet regimen (STaR) trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate in antiretroviral treatment-naive adults infected with HIV-1 through 48 weeks of treatment. Wilkins EL; Cohen CJ; Trottier B; Esser S; Smith DE; Haas B; Brinson C; Garner W; Chuck S; Thorpe D; De-Oertel S AIDS Care; 2016; 28(3):401-8. PubMed ID: 26489045 [TBL] [Abstract][Full Text] [Related]
13. 96-week resistance analyses of the STaR study: rilpivirine/emtricitabine/tenofovir DF versus efavirenz/emtricitabine/tenofovir DF in antiretroviral-naive, HIV-1-infected subjects. Porter DP; Kulkarni R; Fralich T; Miller MD; White KL HIV Clin Trials; 2015; 16(1):30-8. PubMed ID: 25777187 [TBL] [Abstract][Full Text] [Related]
14. Bone turnover change after randomized switch from tenofovir disoproxil to tenofovir alafenamide fumarate in men with HIV. Moore AEB; Burns JE; Sally D; Milinkovic A; Krokos G; John J; Rookyard C; Borca A; Pool ERM; Tostevin A; Harman A; Dulnoan DS; Gilson R; Arenas-Pinto A; Cook GJR; Saunders J; Dunn D; Blake GM; Pett SL AIDS; 2024 Mar; 38(4):521-529. PubMed ID: 38061030 [TBL] [Abstract][Full Text] [Related]
15. Stable Caloric Intake and Continued Virologic Suppression for HIV-Positive Antiretroviral Treatment-Experienced Women After Switching to a Single-Tablet Regimen of Emtricitabine, Rilpivirine, and Tenofovir Disoproxil Fumarate. Menezes P; Mollan K; Hoffman E; Xie Z; Wills J; Marcus C; Rublein J; Hudgens M; Eron JJ AIDS Res Hum Retroviruses; 2018 Jun; 34(6):481-485. PubMed ID: 29607652 [TBL] [Abstract][Full Text] [Related]
16. Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients. Ogbuagu O Expert Rev Anti Infect Ther; 2016 Dec; 14(12):1113-1126. PubMed ID: 27797606 [TBL] [Abstract][Full Text] [Related]
17. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study. Giacomelli A; Conti F; Pezzati L; Oreni L; Ridolfo AL; Morena V; Bonazzetti C; Pagani G; Formenti T; Galli M; Rusconi S BMC Infect Dis; 2021 Jun; 21(1):595. PubMed ID: 34157984 [TBL] [Abstract][Full Text] [Related]
18. Satisfaction and knowledge among patients with HIV after switching from tenofovir to tenofovir alafenamide in regimens containing emtricitabine and rilpivirine. Vélez-Díaz-Pallarés M; Gramage-Caro T; Rodríguez-Sagrado MÁ; Montero-Llorente B; Bermejo-Vicedo T Biomedica; 2020 May; 40(Supl. 1):132-138. PubMed ID: 32463615 [TBL] [Abstract][Full Text] [Related]